Home
PALI
PALI News

Latest Palisade Bio Inc. (PALI) News on October 31, 2025

MT Newswires

11 days ago

Palisade Bio Says First Patients Dosed in Phase 1b Trial of PALI-2108 to Treat Fibrostenotic Crohn's Disease

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

GlobeNewswire

11 days ago

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

MT Newswires

18 days ago

Palisade Bio Receives Canadian Patent for Composition of Product Candidate PALI-2108

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

GlobeNewswire

18 days ago

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

GlobeNewswire

22 days ago

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

GlobeNewswire

5 months ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

GlobeNewswire

6 months ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

GlobeNewswire

6 months ago

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

GlobeNewswire

7 months ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

GlobeNewswire

8 months ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

GlobeNewswire

8 months ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment

GlobeNewswire

8 months ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

GlobeNewswire

8 months ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire

8 months ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

GlobeNewswire

9 months ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

GlobeNewswire

9 months ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

GlobeNewswire

9 months ago

Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

GlobeNewswire

9 months ago

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

GlobeNewswire

10 months ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

GlobeNewswire

a year ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

GlobeNewswire

a year ago

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

GlobeNewswire

a year ago

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

GlobeNewswire

a year ago

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

GlobeNewswire

a year ago

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

GlobeNewswire

a year ago

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

GlobeNewswire

a year ago

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

GlobeNewswire

a year ago

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting

GlobeNewswire

a year ago

Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

GlobeNewswire

a year ago

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

GlobeNewswire

a year ago

Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

GlobeNewswire

a year ago

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies

GlobeNewswire

a year ago

Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

GlobeNewswire

a year ago

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

GlobeNewswire

a year ago

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio Participates in Virtual Investor “What this Means” Segment

GlobeNewswire

a year ago

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

GlobeNewswire

a year ago

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

GlobeNewswire

a year ago

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

GlobeNewswire

a year ago

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

GlobeNewswire

a year ago

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

GlobeNewswire

a year ago

Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

GlobeNewswire

a year ago

Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

Palisade Bio to Present at the Virtual Investor Pitch Conference

GlobeNewswire

a year ago

Palisade Bio to Present at the Virtual Investor Pitch Conference

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

GlobeNewswire

a year ago

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

Palisade Bio Appoints Margery Fischbein to its Board of Directors

GlobeNewswire

a year ago

Palisade Bio Appoints Margery Fischbein to its Board of Directors

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

GlobeNewswire

a year ago

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

GlobeNewswire

a year ago

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

GlobeNewswire

a year ago

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

GlobeNewswire

2 years ago

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

GlobeNewswire

2 years ago

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio to Participate in the Virtual Investor Lunch Break Event

GlobeNewswire

2 years ago

Palisade Bio to Participate in the Virtual Investor Lunch Break Event

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™

GlobeNewswire

2 years ago

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™

Palisade Bio Announces 1-for-15 Reverse Stock Split

GlobeNewswire

2 years ago

Palisade Bio Announces 1-for-15 Reverse Stock Split

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

GlobeNewswire

2 years ago

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

GlobeNewswire

2 years ago

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Palisade Bio Provides Corporate Update and Reiterates Guidance

GlobeNewswire

2 years ago

Palisade Bio Provides Corporate Update and Reiterates Guidance

Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members

GlobeNewswire

2 years ago

Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

GlobeNewswire

2 years ago

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million

GlobeNewswire

2 years ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 01/30/2024

Uxin to Hold an Extraordinary General Meeting on March 1, 2024

PR Newswire

2 years ago

Uxin to Hold an Extraordinary General Meeting on March 1, 2024

Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress

GlobeNewswire

2 years ago

Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 01/29/2024

AppTech Payments Announces Strategic Partnership with First Inning Ventures to Expand Commerse™ Suite in the International and Domestic Sports Market

GlobeNewswire

2 years ago

AppTech Payments Announces Strategic Partnership with First Inning Ventures to Expand Commerse™ Suite in the International and Domestic Sports Market

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 01/26/2024

Forbes-Approved: CareCloud is Streamlining Healthcare with Smart Technology for All Practices

GlobeNewswire

2 years ago

Forbes-Approved: CareCloud is Streamlining Healthcare with Smart Technology for All Practices

Lofty Unveils AI Powered Virtual Assistant at Inman Connect New York

GlobeNewswire

2 years ago

Lofty Unveils AI Powered Virtual Assistant at Inman Connect New York

Ampliphae, HPE Athonet and Arqit deliver Quantum-Safe Private 5G using Symmetric Key Agreement

GlobeNewswire

2 years ago

Ampliphae, HPE Athonet and Arqit deliver Quantum-Safe Private 5G using Symmetric Key Agreement

ElectraMeccanica and Xos Host Joint Investor Call to Provide Shareholder Update

GlobeNewswire

2 years ago

ElectraMeccanica and Xos Host Joint Investor Call to Provide Shareholder Update

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

GlobeNewswire

2 years ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

CareCloud Elevates Pathology Practice siParadigm with Cutting-Edge CareCloud Central Platform

GlobeNewswire

2 years ago

CareCloud Elevates Pathology Practice siParadigm with Cutting-Edge CareCloud Central Platform

Vintage Wine Estates Restructures Organization, Initiates Cost Cuts and Simplifies Business Model

Business Wire

2 years ago

Vintage Wine Estates Restructures Organization, Initiates Cost Cuts and Simplifies Business Model

Business Wire

2 years ago

Xos and ElectraMeccanica Announce Proposed Combination to Accelerate Xos’ Leadership Position in Manufacturing Commercial Electric Vehicles for Major U.S. Fleet Customers

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue

GlobeNewswire

2 years ago

Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenue

Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress

GlobeNewswire

2 years ago

Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress

Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update

GlobeNewswire

2 years ago

Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update

Trust Stamp publishes a White Paper on the potential impact of Quantum Computing on legacy biometric systems

GlobeNewswire

2 years ago

Trust Stamp publishes a White Paper on the potential impact of Quantum Computing on legacy biometric systems

Asensus Surgical Completes In Vivo Surgeon Lab for LUNA Surgical Robotic System

GlobeNewswire

2 years ago

Asensus Surgical Completes In Vivo Surgeon Lab for LUNA Surgical Robotic System

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO

Zacks

2 years ago

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO

Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

GlobeNewswire

2 years ago

Samsung Biologics selects Rapid Micro Biosystems’ Growth Direct® platform to automate critical microbiology quality control testing

PINTEC ANNOUNCES UNAUDITED FINANCIAL RESULTS FOR THE FIRST HALF OF 2023

PR Newswire

2 years ago

PINTEC ANNOUNCES UNAUDITED FINANCIAL RESULTS FOR THE FIRST HALF OF 2023

Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108

GlobeNewswire

2 years ago

Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $1.5 Million Registered Direct Offering for BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN)

ACCESSWIRE

2 years ago

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $1.5 Million Registered Direct Offering for BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN)

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Business Wire

2 years ago

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Sonim Technologies, Inc.'s (NASDAQ:SONM) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Simply Wall St.

2 years ago

Sonim Technologies, Inc.'s (NASDAQ:SONM) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

There’s an EV Delivery Event Today. It’s Different From the Cybertruck One.

Barrons.com

2 years ago

There’s an EV Delivery Event Today. It’s Different From the Cybertruck One.

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q4 2023 Earnings Call Transcript

Zentek and 1Click Heating and Cooling Sign Distribution Agreement

ACCESSWIRE

2 years ago

Zentek and 1Click Heating and Cooling Sign Distribution Agreement

Associated Press Finance

2 years ago

Applied DNA Sciences: Fiscal Q4 Earnings Snapshot

Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results

ACCESSWIRE

2 years ago

Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results

Outlook Therapeutics® Announces Strategic Organizational Realignment

GlobeNewswire

2 years ago

Outlook Therapeutics® Announces Strategic Organizational Realignment

Xos Announces 1-for-30 Reverse Stock Split

GlobeNewswire

2 years ago

Xos Announces 1-for-30 Reverse Stock Split

We Think Some Shareholders May Hesitate To Increase Rave Restaurant Group, Inc.'s (NASDAQ:RAVE) CEO Compensation

Simply Wall St.

2 years ago

We Think Some Shareholders May Hesitate To Increase Rave Restaurant Group, Inc.'s (NASDAQ:RAVE) CEO Compensation

Loss-Making Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected To Breakeven In The Medium-Term

Simply Wall St.

2 years ago

Loss-Making Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected To Breakeven In The Medium-Term

Pleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings Stock

Simply Wall St.

2 years ago

Pleasing Signs As A Number Of Insiders Buy Rani Therapeutics Holdings Stock

AGM Group Holdings Full Year 2022 Earnings: EPS: US$0.47 (vs US$0.17 in FY 2021)

Simply Wall St.

2 years ago

AGM Group Holdings Full Year 2022 Earnings: EPS: US$0.47 (vs US$0.17 in FY 2021)

Duos Technologies Group Reports Third Quarter 2023 Results

GlobeNewswire

2 years ago

Duos Technologies Group Reports Third Quarter 2023 Results

Share on Social Networks: